Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/9/2026 has been entered.
Response to Arguments
Applicant’s arguments with respect to the claim(s) have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. In particular, the prior art of Granger is now being relied upon in combination with McJames and Kato in view of the amendments to the claims.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 5 and 7 is/are rejected under 35 U.S.C. 103 as being unpatentable over McJames, II et al. (US 5,935,138; “McJames”) in view of Kato (JP 2013-241664A; copy with translated abstract provided by applicant on 8/25/2021; a translation of the rest of the document provided by the office with previous action dated 3/5/2025) and Granger et al. (US 5,258,013).
McJames discloses a black-colored medical device comprising a stainless-steel suture needle (abstract; col. 4, ll. 10-15 and 51-57) having a passivation film thereon (oxidation of surface; col. 6, ll. 3-20). McJames further discloses a layer of silicone on the surface of the passivation film (col. 6, ll. 27-35). McJames discloses applying the silicone in a manner that does not fill a recess (14) in the needle (col. 6, ll. 20-27). The silicone is considered an optical adjustment layer as silicone is known to absorb and refract light, noting also that claim 7 claims that the optical adjustment layer is silicone. McJames fails to disclose that the passivation film contains none of hexavalent chromium, cyanide, or lead (noting the use of sodium dichromate in col. 6, ll. 9-11) such that the passivation film is colored from dark brown to blue. Note: the range “dark brown to blue” is understood to include dark brown, reddish purple and blue in view of par. [0020] of the instant application.
Kato discloses that stainless steel can be colored by applying a specific power source using a square wave in an acidic solution containing no hexavalent chromium (see abstract and [0010]). A stable passivation film is formed on the stainless steel (stable oxide film; [0008]-[0010]), and by changing the various conditions of the square wave, it is possible to produce the film in colors such as blue, brown, and black ([0010]). The passivation film contains none of hexavalent chromium, cyanide or lead (see entire document, esp. [0010], [0020], and noting no lead or cyanide are used in the process). It would have been obvious to one of ordinary skill in the art to have modified the prior art stainless steel suture needle of McJames to provide a passivation film formed via the method taught by Kato instead of that disclosed by McJames in order to negate the use of substances that have a severe environmental impact ([0007] of Kato). As taught by Kato, the passivation film may be made blue ([0010], [0017]). It would have been obvious to have colored the passivation film on the needle of McJames as modified in view of Kato to be blue as taught by Kato since the primary purpose of the coloration of the needle is to provide a needle more readily observed by surgeons than conventional shiny needles as noted by McJames (col. 1, ll. 54-59), and a passivation film of blue provides the same dulling effect as understood by one of ordinary skill in the art.
According to the instant application, a layer of silicone over a needle with a blue or brown passivation film formed on stainless steel results in the needle appearing black where the passivation film is present (see [0021] of instant application as filed 8/25/2021). Therefore, it is understood that the needle of McJames in view of Kato, which comprises a stainless-steel needle having a passivation film colored blue as taught by Kato and covered with a layer of silicone as disclosed by McJames, will have a silicone layer that is “blackened” (i.e., the needle will appear black) in the same manner as the instant invention (see [0021] of instant application).
McJames in view of Kato fails to disclose that the needle has an uncoated part the same color as the passivation film (i.e., an uncoated part having the passivation film, but not the silicone).
Granger discloses that it is known to coat needles with silicone by inserting the needle shank end into a support block of rigid foam and thereafter spraying the siliconization fluid to the exposed surface of the needle (col. 3, ll. 62-col. 4, ll. 33). Since the shank end of the needle is embedded in the support block, it remains free of silicone, which advantageously prevents silicone from entering the recess at the end of the needle (col. 3, ll. 62-col. 4, ll. 33).
It would have been obvious to one of ordinary skill in the art to have modified the prior art of McJames to apply the silicone on the needle, which includes a blue passivation film over its outer surface as taught by Kato, using the spray method taught by Granger such that an end portion of the needle remains uncoated with silicone, since such a method allows the bore occluding step disclosed by McJames (col. 6, ll. 20-27) to be totally omitted according to Granger (see col. 3, ll. 65-col. 4, ll. 30 of Granger). With such a modification, the uncoated portion of the needle (i.e. uncoated by silicone) will have the same color as the passivation film (i.e., blue as taught by Kato, which is applied to entire needle as disclosed by McJames) since it is not covered with silicone (which optically adjusts blue passivation film to appear black).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHLEEN SONNETT HOLWERDA whose telephone number is (571)272-5576. The examiner can normally be reached M-F, 8-5, with alternate Fridays off.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached on 571-272-7134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
KSH 3/23/2026
/KATHLEEN S HOLWERDA/Primary Examiner, Art Unit 3771